NeoGenomics Exercises Option To Acquire Remaining Stake In Inivata For $390M

  • NeoGenomics Inc NEO has agreed to acquire the remaining stake in Inivata Ltd, a commercial-stage liquid biopsy platform company headquartered in England.
  • The acquisition follows a $25 million minority equity investment by NeoGenomics in Inivata in May last year, at which time NeoGenomics was granted a fixed price option to purchase the remainder of Inivata for $390 million.
  • The cash purchase price will be funded with balance sheet cash and a private placement of equity, with the expected gross proceeds of $200 million.
  • The acquisition is expected to close concurrently with the private placement in June 2021.
  • Inivata will become a liquid biopsy-focused division alongside NeoGenomics' growing clinical, pharma and informatics divisions. Current Inivata CEO Clive Morris will become the President of Inivata and report to Mark Mallon, CEO of NeoGenomics.
  • Private Placement: NeoGenomics will sell 4.4 million shares at $45.00 per share
  • Price Action: NEO shares down 4.85% to $45.26 in the premarket session on the last check Wednesday.
Loading...
Loading...
NEO Logo
NEONeoGenomics Inc
$8.113.44%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
9.61
Growth
36.08
Quality
-
Value
15.24
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Posted In:
Comments
Loading...